What do we need to know about active ingredients? Workshop #1.

Slides:



Advertisements
Similar presentations
David M. Pollock Medical College of Georgia Discovery-Academia.
Advertisements

1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.
Clinical Expertise Database Sue Watson Head of MedTech Services Health Enterprise East.
Jim Jones Acting Assistant Administrator Office of Chemical Safety & Pollution Prevention 1.
Pharmanex leading the health revolution MISSION n Help people achieve healthier more productive lives THE HEALING POWER OF KNOWLEDGE u Best reputation.
Affordable, Credible, Efficient Research
Phase 0 & Patients From the Patient Side of the Desk September 5, 2007 NCI Phase O Workshop Deborah Collyar PAIR: Patient Advocates In Research.
U.S. FDA Perspective on Food Supplements/TM
Peer Assessment of 5-year Performance ARS National Program 301: Plant, Microbial and Insect Genetic Resources, Genomics and Genetic Improvement Summary.
Regulatory and Industry Requirements for Botanical Drug Products Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics KLE University.
Botanical Research Centers: NIEHS Interests Elizabeth A. Maull, Ph.D. Program Administrator, NIEHS.
DSHEA and Bioavailability Elizabeth A. Yetley, Ph.D. Ctr. Food Safety & Applied Nutrition Food and Drug Administration.
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Marine Ingredients Overview Intrafish Investment Forum, London 2013
International Food Aid and Development Conference M. Ann Tutwiler Global Food Security Coordinator Office of the Secretary, USDA.
Kathryn Camp, M.S., R.D., CSP Consultant to the Office of Dietary Supplements National Institutes of Health Secretary’s Advisory Committee on Heritable.
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
Interoperability to Support a Learning Health System HL7 Learning Health Systems Workgroup.
19/08/2007 KLE University, Belgaum, India1 REGULATORY GUIDELINES FOR PRECLINICAL AND CLINICAL VALIDATION OF TRADITIONAL MEDICINES Dr. Basavaraj K. Nanjwade.
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
Contact Profile
Engaging Stakeholders in the Effective Health Care Program Information and tools for researchers and investigators.
Stefan Franzén Introduction to clinical trials.
ACPS Manufacturing Subcommittee Report October 19, 2004 Judy P. Boehlert, Ph.D. Chair.
EHRs and Meaningful Use: The Case for Semantics Ram D. Sriram Chief, Software and Systems Division Information Technology Laboratory
Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.
What Are They? Who Needs them? What Are They? Who Needs them?
Topic 13 – Lesson Plan Review Facilitation Guideline Zone and Date
Jennifer Barrickman, PhD Student Walden University PUBH Instructor: Howard Rubin, PhD Winter, 2010.
Nutritional Supplement Research: Beyond the Status Quo.
U.S. Action Plan for Acrylamide Activities and Progress Terry Troxell, Ph.D.and Lauren Posnick, Sc.D., U.S. FDA March 16, 2003 FAO/WHO Seminar on Acrylamide.
Update From FDA: Office of the Commissioner and Center for Drug Evaluation and Research Janet Woodcock, M.D. Acting Deputy Commissioner for Operations.
CPTR Overview CPTR 2012 Workshop October 2-4, 2012.
Concept Paper #3: Risk Assessment of Observational Data Session 1: Good Pharmacovigilance Practices Linda S. Hostelley on behalf of PhRMA.
Springer for R&D Food Science. Springer for R&D – Food Science & Nutrition Springer for R&D – rd.springer.comrd.springer.com Immediate Access to Quality.
Major Components of FDA’s Action Plan for Acrylamide Richard Canady, PhD DABT US Food and Drug Administration Center for Food Safety and Applied Nutrition.
Dietary Supplement Research Centers: Botanicals RFA OD Applicant Information Meeting February 6, 2004 Bethesda MD Christine A. Swanson, Ph.D. Office.
Adam Heathfield, PhD Senior Director, Worldwide Policy, Pfizer Inc. September 25, 2013 Personalised Medicine – an industry perspective.
Guidelines for eating right Active Living Dietary Guidelines A set of recommendations about smart eating and planned activity.
1 Pesticide Program Dialogue Committee Meeting State Lead Agency Presentation Chuck Andrews, Chair AAPCO Worker Protection Committee California Department.
RESEARCH NEEDS : BIOAVAILABILITY METHODOLOGY. IN VITRO METHODOLOGIES Develop simple and reliable methods to screen bioavailability of dietary supplements.
1 Abu Alam Ph.D. Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 23, 2008.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances Published by US FDA’s Center for Drug Evaluation and Research June 2009.
Current Plan for Critical Path Initiative Janet Woodcock, M.D. Acting Deputy Commissioner For Operations November 5, 2004.
Vaccine Enterprise & Collaboration Bill Snow, Director 19 January 2013 CHVI Afri-Can Forum.
Alun JONES EU Network Manager European Agency for Safety and Health at Work 6 th Framework Programme on Research.
Methodological Issues in Systematic Review - Formulating Questions - Joseph Lau, MD Tufts Medical Center EPC AHRQ Annual Meeting September 10, 2008.
Pharmacovigilance in HIV/AIDS Public Health Programmes: Luxury or Priority? November 2009, dar Es Salaam.
Bioavailability of Dietary Supplements: Key Issues in Defining the Research Agenda Impact of Formulation on Bioavailability? Discussion Leader: Stephen.
ICARE Member Reports National Institutes of Health/National Institute of Neurological Disorders and Stroke NIH Mission: NIH is the steward of medical and.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
Southern African Pesticidal Plants Project Workpackage 8: Training & Workshops.
Clinical Trial Design and other Statistical Issues Mary A. Foulkes, Ph.D. Office of Biostatistics and Epidemiology Vaccines and Related Biological Products.
1 Destination India: Contract Research in Pharmaceuticals & Healthcare S.P. Vasireddi, Ph.D Chairman, ACRO 26/03/2009.
IADSA Scientific Forum 2009 The scientific substantiation of health claims David P. Richardson Scientific Adviser to UK Council for Responsible Nutrition.
Industry Sessions : Natural Product Research and IUPHAR
Methodological Issues and Techniques
Group on Neural Issues.
Privacy at National Institutes of Health Clinical Center
ECE 214 Innovative Education-- snaptutorial.com
Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials.gov Content downloaded: September 2012.
“One size does not fit all”
Registration is Open:
MIDD: Perspectives and Possibilities
Volume 21, Issue 9, Pages (September 2014)
Omega-3s vs Pure EPA in Clinical Practice
Nutrition. Good Food Health.
Presentation transcript:

What do we need to know about active ingredients? Workshop #1

Discussion focus--Botanicals Question— Are traditional nutritional and pharmacological approaches applicable to herbal supplements? Multiple biologically active substances in products Multiple biological activity endpoints

Identifying meaningful components Meaningful = Components that produce a biological effect Identification of meaningful components should precede study of their bioavailability Analytical chemistry databases inadequate for botanicals

Analytical database development NAPRALERT, IBIDS—good sources, need to expand knowledge base internationally USDA databases as models

Reference materials Standardized products needed for research Dietary fiber & fish oil standard products as models Industry should collaboratively develop—nonproprietary, best first guess as to efficacy/safety USP certification

Clinical trials Need standard reference products Use classical approach (Phase I, II, etc..) Determine priorities for clinical trials Selection criteria? Extent of use Efficacy—target major public health issues Safety

Bioassays potential screening tools use with caution No substitute for clinical studies

Biomarkers Little progress to date May be useful

Summary Identification of meaningful (bioactive) components should be the main focus Bioavailability may be a key determinant of bioactivity Need for standard reference materials Clinical studies should be based on these 3 research areas